System1 Biosciences, Inc., is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These 'deep phenotypes' are exploited to identify novel therapeutic targets and drug treatments.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/12/18 | $25,000,000 | Series A |
Alexandria Real Estate Equities Boom Capital Charles River Ventures  Dolby Family Ventures Kinled Holding Liquid 2 Ventures Longevity Fund Pfizer Strategic Investments Group Riot Ventures Webb Investment Network Wilmot Ventures | undisclosed |
